CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Price, Forecast & Analysis
USA - NASDAQ:CMMB - US16385C2035 - ADR
CMMB Key Statistics, Chart & Performance
The current stock price of CMMB is 2.65 USD. In the past month the price decreased by -22.26%. In the past year, price decreased by -61.94%.
CMMB Latest News, Press Relases and Analysis
CMMB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.79 | 413.89B | ||
| AMGN | AMGEN INC | 15.5 | 182.48B | ||
| GILD | GILEAD SCIENCES INC | 15.27 | 155.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.36 | 112.89B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.42 | 73.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 891.92 | 59.63B | ||
| INSM | INSMED INC | N/A | 41.07B | ||
| NTRA | NATERA INC | N/A | 28.01B | ||
| BIIB | BIOGEN INC | 10.05 | 24.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.75 | 21.18B | ||
| INCY | INCYTE CORP | 16.47 | 20.64B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.61 | 14.35B |
Related stock screener links
About CMMB
Company Profile
Chemomab Therapeutics Ltd. is a clinical-stage biotech company, which engages in the provision of therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Company Info
CHEMOMAB THERAPEUTICS LTD
Kiryat Atidim, Building 7
TEL AVIV-YAFO 02139 IL
CEO: Neil Cohen
Employees: 16
Phone: 972773310156
CHEMOMAB THERAPEUTICS LTD / CMMB FAQ
Can you describe the business of CHEMOMAB THERAPEUTICS LTD?
Chemomab Therapeutics Ltd. is a clinical-stage biotech company, which engages in the provision of therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
What is the stock price of CHEMOMAB THERAPEUTICS LTD today?
The current stock price of CMMB is 2.65 USD. The price increased by 3.92% in the last trading session.
Does CMMB stock pay dividends?
CMMB does not pay a dividend.
What is the ChartMill rating of CHEMOMAB THERAPEUTICS LTD stock?
CMMB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does CHEMOMAB THERAPEUTICS LTD belong to?
CHEMOMAB THERAPEUTICS LTD (CMMB) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of CHEMOMAB THERAPEUTICS LTD (CMMB)?
CHEMOMAB THERAPEUTICS LTD (CMMB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.76).
CMMB Technical Analysis
CMMB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CMMB. CMMB has a great financial health rating, but its profitability evaluates not so good.
CMMB Financial Highlights
Over the last trailing twelve months CMMB reported a non-GAAP Earnings per Share(EPS) of -2.76. The EPS increased by 92.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -106.24% | ||
| ROE | -121.9% | ||
| Debt/Equity | 0 |
CMMB Forecast & Estimates
8 analysts have analysed CMMB and the average price target is 27.03 USD. This implies a price increase of 920% is expected in the next year compared to the current price of 2.65.